Vaspin Levels Research Articles

Astaxanthin Supplementation Augments the Benefits of CrossFit Workouts on Semaphorin 3C and Other Adipokines in Males with Obesity.

Regular physical activity and the use of nutritional supplements, including antioxidants, are recognized as efficacious approaches for the prevention and mitigation of obesity-related complications. This study investigated the effects of 12 weeks of CrossFit training combined with astaxanthin (ASX) supplementation on some plasma adipokines in males with obesity. Sixty-eight males with obesity (BMI: 33.6 ± 1.4 kg·m-2) were randomly assigned into four groups: the control group (CG; n = 11), ASX supplementation group (SG; n = 11), CrossFit group (TG; n = 11), and training plus supplement group (TSG; n = 11). Participants underwent 12 weeks of supplementation with ASX or placebo (20 mg/day capsule daily), CrossFit training, or a combination of both interventions. Plasma levels of semaphorin 3C (SEMA3C), apelin, chemerin, omentin1, visfatin, resistin, adiponectin, leptin, vaspin, and RBP4 were measured 72 h before the first training session and after the last training session. The plasma levels of all measured adipokines were significantly altered in SG, TG, and TSG groups (p < 0.05). The reduction of resistin was significantly higher in TSG than in SG (p < 0.05). The plasma levels of omentin1 were significantly higher in both training groups of TG and TSG than SG (p < 0.05), although such a meaningful difference was not observed between both training groups (p > 0.05). Significant differences were found in the reductions of plasma levels of vaspin, visfatin, apelin, RBP4, chemerin, and SEMA3C between the SG and TSG groups (p < 0.05). The study found that a 12-week intervention using ASX supplementation and CrossFit exercises resulted in significant improvements in several adipokines among male individuals with obesity. Notably, the combined approach of supplementation and training had the most pronounced results. The findings presented in this study indicate that the supplementation of ASX and participation in CrossFit exercise have the potential to be effective therapies in mitigating complications associated with obesity and enhancing metabolic health.

Correlation between Serum Levels of Vaspin, BMI, and Waist Circumference on Obese and Non-Obese Subjects

Obesity is the accumulation of excessive fat resulting from an imbalance in energy intake compared to energy used for a long period. Vaspin is secreted in adipose tissue and may exhibit compensatory responses related to obesity, insulin resistance, and type 2 diabetes mellitus. This study aimed to determine vaspin levels in obese and non-obese subjects. An observational research design with a cross-sectional approach was used in this study. A total of 80 research subjects were included in this study. The research was conducted at the Clinical Pathology Laboratory at the Department of Clinical Pathology, Hasanuddin University Hospital in January 2022. Kolmogorov-Smirnov test was used to determine the normality of the data. Chi-Square, unpaired T-test, Mann-Whitney test, and Spearman test were used as statistical tests. This study showed a significant difference in anthropometric parameters between the obese and non-obese groups (p &lt; 0.001). There was a significant difference in the mean levels of vaspin between the obese and non-obese groups (707.68±774.47 ng/mL vs. 510.60±460.08 ng/mL, p=0.004). There was a positive correlation between vaspin levels and waist circumference (r = 0.245, p=0.004) and between vaspin levels and BMI (r = 0.322, p=0.028). The serum levels of vaspin tended to be higher in obese subjects compared to non-obese subjects. The positive correlation between vaspin levels and BMI and waist circumference indicated that a higher BMI and/or waist circumference led to a higher vaspin level.

Serum Vaspin Levels in Gestational Diabetes Mellitus: A Meta-Analysis.

The objective of this study was to evaluate the potential relationship between serum vaspin levels and gestational diabetes mellitus (GDM). The PubMed, EBSCO, Web of Science, the Cochrane Library, and the China National Knowledge Infrastructure (CNKI) database were searched for articles published before December 2022. The publication language was restricted to English and Chinese. A meta-analysis was conducted by combining all studies that met the inclusion and exclusion criteria. Twenty-two studies (1990 women with GDM and 1597 pregnant women without GDM) were ultimately included in this meta-analysis. The meta-analysis showed that the serum vaspin levels are significantly higher in GDM compared with the controls (standardized mean difference: 0.720, 95% confidence interval: 0.440-1.000, Z = 5.041, P < 0.001). Subgroup analyses by stage of pregnancy and body mass index showed results similar to the overall outcome. No publication bias was identified, and the sensitivity analysis confirmed the robustness of the final result. Our results show that the serum vaspin levels are significantly higher in GDM. These findings suggest that high vaspin concentration is closely related to GDM and the serum vaspin levels might be a potential biomarker to indicate risk of GDM, more randomized control trials comparing the expression levels of vaspin between early and standard diagnosis of GDM are needed to strengthen our findings.

The potential value of some adipokines and cytokines as diagnostic biomarkers for prostate cancer

Abstract Background: The role of Adipokines and proinflammatory cytokines is said to be crucial in the development of prostate cancer. Vaspin, Chemerin, Omentin, Interleukins IL-1β, interleukin-8 (IL8), Colony-stimulating factor (GM-CSF) and CC chemokine ligand 18 (CCL18) have all been proven to take part in tumor growth and progression. Aim of the study: The study aimed to explore circulating novel adipocytokines, such as serum of Vaspin, Chemerin and Omentin levels in patients with prostate cancer and to determine the level of selected proinflammatory cytokines (CCL18, IL-8, IL1, and GM-CSF). Methods: Three groups were included in the current study: Group (1) :32 patients with metastatic prostate cancer who received chemotherapy, Group (2): 30 untreated patients with nonmetastatic prostate cancer, and Group (3): 30 healthy controls. ELISA technique was used to assess serum levels of Vaspin, Chemerin, Omentin, CCL18, IL-8, IL1, and GM-CSF). Results: The Prostate cancer group exhibited higher serum levels of Vaspin, Chemerin, Omentin, CCL18, IL-8, IL1, and GM-CSF compared to the control group. Chemotherapy-treated patients exhibited significantly increased levels of the pro-inflammatory cytokines (IL-8) and Adipokines (Vaspin and Omentin) and decreased levels of the pro-inflammatory cytokines (IL-1) and Adipokines (Chemerin). The correlation analysis showed a significant positive correlation of serum Chemerin with Vaspin (r = 0.957, p-value&lt;0.0001), IL-8 (r = 0.9475, p-value &lt; 0.0001) and IL-1β (r = 0.7771, p-value &lt; 0.0029). Omentin and GS-CSF levels showed a non-significant positive correlation with Chemerin level (r = 0.1259; p = 0.6967).) and (r = 0.4247; p = 0.1688), respectively. While significant negative correlation was found between (Chemerin) with CCL-18 (r = –0.7916, p = 0.0022), serum Vaspin was significantly and negatively correlated with the levels of CCL-18 (r = –0.9349, p &lt; 0.0001), whereas there was a significant positive correlation between Vaspin level with IL-8 (R=0.9995, p &lt;0.0001); IL-1β(r = 0.561, p = 0.0057). The data demonstrated that Vaspin was positively and non-significantly correlated with the level of GS-CSF (r = 0.1437, p =0.656); serum Omentin was significantly and negatively correlated with the levels of GS-CSF (r = –0.8447, p = 0.0005), and CCL-18 (r= –0.7058, p = 0.0103), whereas there was a non-significant positive correlation between Omentin level with IL-8 (r = 0.4364, p = 0.1561). The data demonstrated that Omentin was negatively and non-significantly correlated with the level of IL-1β (r= –0.5366, p =0.0786). Conclusions: This study indicated increased levels of serum Vaspin, Chemerin, Omentin, Interleukins IL-1β, interleukin-8 (IL8), Colony-stimulating factor (GM-CSF) and CC chemokine ligand 18 (CCL18) in patients with Prostate cancer. These findings suggest that the cytokines, and adipokines, whose levels were elevated in the chemotherapy-treated patients may be involved in the pathophysiology of prostate cancer. Vaspin, Chemerin and Omentin might play an important role in Prostate cancer progression through their association with Adipokines and proinflammatory cytokines. More studies are needed to investigate the possible role of Vaspin, Chemerin and Omentin as potential markers in the development of Prostate cancer.

Comparison between Serum Vaspin in Chronic Kidney Disease and with Hepatitis C Virus and Normal Control Group

Abstract Background Chronic kidney disease ―CKD|| patients have insulin secretion disorders and resistance to insulin effects, that is responsible for the development of cardiovascular proceedings. Vaspin is an adipcytokine that regulates glucose and lipid metabolism. Aim and objectives To compare serum level of Vaspin in Chronic kidney disease&amp; chronic hepatitis C patients group and normal control group. Subjects and Methods This study is comparative case - control study, was conducted at in Ain shams university hospitals &amp; El Zaitoun Specialized hospital on patients attending gastroenterology and hepatology clinic and nephrology clinic0. Result There was high statistically significant difference between the studied groups as regard vaspin. Conclusion Diabetic nephropathy‖ patients presented a significant increased levels of serum Vaspin when compared to levels to control, serum Vaspin are protective roles. Also, vaspin could be used as specific predictors for liver fibrosis in CHC patients with and without diabetes.

Supplementation with spinach-derived thylakoid augments the benefits of high intensity training on adipokines, insulin resistance and lipid profiles in males with obesity.

This study investigated the effects of 12 weeks of high-intensity functional training (HIFT) combined with spinach-derived thylakoid supplementation on some selected Adipokines and insulin resistance in males with obesity. Sixty-eight participants (mean age: 27.6 ± 8.4 yrs.; mean height: 168.4 ± 2.6cm; mean weight: 95.7 ± 3.8kg, mean BMI: 32.6 ± 2.6 kg/m2) were randomly divided into four groups of 17 per group: Control group (CG), Supplement group (SG), Training group (TG), and Training + supplement group (TSG). Following baseline measurements, the two training groups (TG and TSG) started the 12 weeks of exercise training program (3 sessions per week). A total of 36 sessions lasting up to 60min were included in the HIFT program using the CrossFit program. The eligible participants received 5 g/day of thylakoid-rich spinach extract or matching placebo as 5 g/day of raw corn starch (one sachet, 30min before lunch) for 12 weeks. Baseline assessments were obtained 48 hours before the start of the training protocols and 48 hours after the last training session in all groups. There were significant interactions (p<0.001 for all) between exercise and time for adiponectin (ES:0.48), leptin (ES:0.46), resistin (ES:0.3), omentin (ES:0.65), vaspin (ES:0.46), visfatin (ES:0.62), apelin (ES:0.42), RBP4 (ES:0.63), chemrin (0.36) and semaphorin3c (ES: 0.5). Plasma levels of semaphorin3c were significantly correlated (p<0.05) with body weight (r= 0.57), BMI (r= 0.43), FFM (r= -0.612), FAT (r= 0.768), VO2peak (r=-0.53), insulin (r= 0.756), glucose (r= 0.623), and HOMA-IR (r= 0.727). There were also significant group differences in insulin (ES: 0.77), glucose (ES: 0.21), and HOM-IR (ES: 0.44) (p<0.05). Our findings indicate that 12 weeks of HIFT supplemented with spinach-derived thylakoid reduced levels of leptin, resistin, vaspin, visfatin, apelin, RBP4, chemrin, semaphorin3c and insulin resistance while increasing adiponectin and omentin levels in men with obesity.

Plasma vaspin levels and clinical outcome in incident peritoneal dialysis patients

BackgroundVaspin is an adipokine that regulates glucose and lipid metabolism. Plasma vaspin level is increased in chronic kidney disease but decreased in hemodialysis patients. However, plasma vaspin level in peritoneal dialysis (PD) patients, as well as its prognostic role, has not been studied.MethodsWe recruited 146 incident PD patients. Their baseline plasma vaspin levels, body anthropometry, the profile of insulin resistance, bioimpedance spectroscopy parameters, dialysis adequacy, and nutritional indices were measured. They were followed for up to 5 years for survival analysis.ResultsThe average age was 58.4 ± 11.8 years; 96 patients (65.8%) were men, and 90 (61.6%) had diabetes. The median vaspin level was 0.18 ng/dL (interquartile range [IQR] 0.11 to 0.30 ng/dL). Plasma vaspin level did not have a significant correlation with adipose tissue mass or baseline insulin level. However, plasma vaspin level had a modest correlation with the change in insulin resistance, as represented by the HOMA-IR index, in non-diabetic patients (r = -0.358, p = 0.048). Although the plasma vaspin level quartile did not have a significant association with patient survival in the entire cohort, it had a significant interaction with diabetic status (p < 0.001). In nondiabetic patients, plasma vaspin level quartile was an independent predictor of patient survival after adjusting for confounding clinical factors (adjusted hazard ratio 2.038, 95% confidence interval 1.191–3.487, p = 0.009), while the result for diabetic patients was not significant.ConclusionsPlasma vaspin level quartile had a significant association with patient survival in non-diabetic PD patients. Baseline plasma vaspin level also had a modest inverse correlation with the subsequent change in the severity of insulin resistance, but the exact biological role of vaspin deserves further studies.

Levels and diagnostic values of serum visceral adipose tissue-derived serine protease inhibitor and secreted frizzle-related protein 5 in children with idiopathic short stature

Abstract Background: Idiopathic short stature (ISS) is a common type of short stature. We aimed to analyze the diagnostic values of serum visceral adipose tissue-derived serine protease inhibitor (Vaspin) and secreted frizzle-related protein 5 (SFRP5) for ISS children. Methods: Sixty-five ISS children treated from February 2019 to June 2022 were selected as an ISS group, while another 65 healthy children receiving physical examination in the same period were selected as a healthy group. Their general data, physical development status, levels of serum Vaspin and SFRP5, and levels of serum growth hormone-releasing hormone (GHRH)/growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis-related indicators were compared. Results: The ISS group had lower body height, body weight, bone age, growth velocity and serum SFRP5 level and higher serum Vaspin level than those of the healthy group (P&lt;0.05). The levels of serum GHRH, GH and IGF-1 were lower in the ISS group than those in the healthy group (P&lt;0.05). Body height, body weight, bone age, growth velocity, and levels of GHRH, GH and IGF-1 were negatively correlated with serum Vaspin level (r&lt;0, P&lt;0.05) but positively correlated with serum SFRP5 level (r&gt;0, P&lt;0.05). The areas under the ROC curves of serum Vaspin and SFRP5 and their combination for the diagnosis of ISS were 0.871 [95% confidence interval (CI): 0.812-0.929], 0.880 (95% CI: 0.824-0.935) and 0.942 (95% CI: 0.907-0.977), respectively. Conclusions: Children with ISS have a higher level of serum Vaspin but a lower level of SFRP5, and the combined detection has a higher diagnostic value for ISS.

Diyabetik olmayan ST yükselmesiz miyokard enfarktüsü hastalarında serum vaspin düzeyi ile coroner arter hastalığının şiddeti arasındaki ilişki

Objectives: Vaspin is an adipocytokine, serine protease inhibitor, correlated to obesity, insülin sensitivity, diabetes mellitus, and coronary artery disease. The association between vaspin and coronary artery disease was shown in several studies. Whether this value is independent of diabetes in coronary artery disease patients is not known. Also, a study that shows the importance of vaspin in patients with Non-ST elevation myocardial infarction (NONSTEMI) is not conducted. This study aimed to investigate the relationship between serum vaspin levels and the severity of coronary artery disease, which is determined by the SYNTAX score, in nondiabetic patients with NONSTEMI&#x0D; Methods: A total of 165 nondiabetic patients with NONSTEMI were included prospectively. Serum vaspin levels were measured by the ELISA method.SYNTAX scores were evaluated by two expert operators blinded to the angiography results. Patients were divided into three groups according to the SYNTAX score by the interquartile range method (group 1 with SS 22).&#x0D; Results: Serum vaspin levels were found significantly different between three groups (p = 0,03) and significantly higher in group 1 than group 3 (p = 0,01).No significant difference was found between group 1 and 2 also group 2 and 3 (p = 0, 52, p = 0.06 ).It was found to be a significant but weak negative correlation between the SYNTAX score and serum vaspin levels (r = -0,207, p = 0.008).&#x0D; Conclusion: Vaspin negatively correlates to SYNTAX score and maybe a useful marker to show the severity of coronary disease in nondiabetic patients with NONSTEMI

Vaspin alleviates pathological cardiac hypertrophy by regulating autophagy-dependent myocardial senescence

Abstract Background Visceral adipose tissue–derived serine protease inhibitor (vaspin), a secretory adipokine, protects against insulin resistance. Recent studies have demonstrated that serum vaspin levels are decreased in patients with coronary artery disease and that vaspin protects against myocardial ischemia-reperfusion injury and atherosclerosis. However, it remains unclear whether vaspin exerts specific effects on pathological cardiac hypertrophy. Methods An in vivo study was conducted using a cardiac hypertrophy model established by subcutaneous injection of isoproterenol (ISO) in C57BL/6 and vaspin-ko mice. Rapamycin was administered intraperitoneally to mice, for further study. H9c2 cells and neonatal rat ventricular myocytes (NRVMs) were treated with ISO to induce hypertrophy. Human vaspin fusion protein, the proteasome inhibitor MG132, and chloroquine diphosphate were used for further mechanistic studies. Results Here, we provide the first evidence that vaspin knockdown results in markedly exaggerated cardiac hypertrophy, fibrosis, and cardiomyocyte senescence in mice treated with ISO. Conversely, the administration of exogenous recombinant human vaspin protected NRVMs in vitro against ISO-induced hypertrophy and senescence. Furthermore, vaspin significantly potentiated the ISO-induced decrease in autophagy. Both rapamycin and chloroquine diphosphate regulated autophagy in vivo and in vitro, respectively, and participated in vaspin-mediated cardioprotection. Moreover, the PI3K-AKT-mTOR pathway plays a critical role in vaspin-mediated autophagy in cardiac tissues and NRVMs. Our data showed that vaspin downregulated the p85 and p110 subunits of PI3K by linking p85 and p110 to NEDD4L-mediated ubiquitination degradation. Conclusion Our results show, for the first time, that vaspin functions as a critical regulator that alleviates pathological cardiac hypertrophy by regulating autophagy-dependent myocardial senescence, providing potential preventive and therapeutic targets for pathological cardiac hypertrophy.

Expression of Locally Produced Adipokines and Their Receptors during Different Physiological and Reproductive Stages in the Bovine Corpus Luteum.

This study aimed to determine the gene expression of different local novel adipokines, such as vaspin, adiponectin, visfatin, and resistin, and their known receptors, namely, heat shock 70 protein 5, adiponectin receptor 1, and adiponectin receptor 2, in the bovine corpus luteum (CL) during different phases of the estrous cycle (on days 1-2, 3-4, 5-7, 8-12, 13-18, >18) and pregnancy (at months 1-2, 3-4, 5-7, >7). The mRNA expression was measured by reverse transcription polymerase chain reaction (RT-qPCR). The mRNA expression levels were normalized to the geometric mean of all three constantly expressed reference genes (cyclophilin A, ubiquitin, ubiquitin C). Our findings suggest that adipokines are expressed and present in all investigated groups, and are specifically up- or downregulated during the estrus cycle and during pregnancy. Vaspin and adiponectin levels were upregulated in the middle and late cycle stages. Resistin was abundant during the CL regression stage and in the first months of pregnancy. The specific expression of adipokine receptors indicates their involvement in the local mechanisms that regulate CL function. Further investigations are required to elucidate the regulative mechanisms underlying the different local effects of adipokines on the ovarian physiology of cows.

Overexpressing high levels of human vaspin limits high fat diet-induced obesity and enhances energy expenditure in a transgenic mouse.

Adipose tissue inflammation and insulin resistance are hallmarks in the development of metabolic diseases resulting from overweight and obesity, such as type 2 diabetes and non-alcoholic fatty liver disease. In obesity, adipocytes predominantly secrete proinflammatory adipokines that further promote adipose tissue dysfunction with negative effects on local and systemic insulin sensitivity. Expression of the serpin vaspin (SERPINA12) is also increased in obesity and type 2 diabetes, but exhibits compensatory roles in inflammation and insulin resistance. This has in part been demonstrated using vaspin-transgenic mice. We here report a new mouse line (h-vaspinTG) with transgenic expression of human vaspin in adipose tissue that reaches vaspin concentrations three orders of magnitude higher than wild type controls (>200 ng/ml). Phenotyping under chow and high-fat diet conditions included glucose-tolerance tests, measurements of energy expenditure and circulating parameters, adipose tissue and liver histology. Also, ex vivo glucose uptake in isolated adipocytes and skeletal muscle was analyzed in h-vaspinTG and littermate controls. The results confirmed previous findings, revealing a strong reduction in diet-induced weight gain, fat mass, hyperinsulinemia, -glycemia and -cholesterolemia as well as fatty liver. Insulin sensitivity in adipose tissue and muscle was not altered. The h-vaspinTG mice showed increased energy expenditure under high fat diet conditions, that may explain reduced weight gain and overall metabolic improvements. In conclusion, this novel human vaspin-transgenic mouse line will be a valuable research tool to delineate whole-body, tissue- and cell-specific effects of vaspin in health and disease.

FUNCTIONAL ROLE OF THE TP53 GENE SINGLE NUCLEOTIDE POLYMORPHISM P72R (C&gt;G) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS OF THE EAST UKRAINIAN POPULATION

Recently, the role of stress-regulatory pathways in the development and progression of type 2 diabetes mellitus (T2DM) and associated cardiovascular diseases has been widely investigated. The aim of the study was to assess the relationship of polymorphic variants P72R (C&gt;G) of the TP53 gene with the functional and metabolic characteristics of type 2 diabetic patients in the East Ukrainian population. Materials and methods. 50 T2DM patients (female/male: 21/29) aged 53.34±1.43 yrs., with diabetes duration of 6.25±0.89 yrs., HbA1c level of 7.12±0.21%, body mass index of 31.19±0.93 kg/m2, with waist-to-hip ratio of 0.96±0.01, with the presence of coronary heart disease in 38 cases, hypertension in 46 cases, and their combination in 37 cases. Characteristics of carbohydrate/lipid metabolism, parameters of insulin resistance, chronic inflammation, and a number of adipokines were determined in the subjects. Genotyping for single nucleotide polymorphism P72R (C&gt;G) TP53 was performed by the method of polymerase chain reaction with appropriate primers and BstUI endonuclease. Testing of null hypotheses was carried out using the t, F and c2 criteria at the significance level of P≤0.05. Results. There was a noticeable tendency (P=0.05) to increase in frequency of the recessive allele G, mainly in men, which requires further extended studies. In addition, carriers of the minor genotype are characterized by a significantly younger age of T2DM manifestation. Under the statistically similar parameters that characterize the degree of obesity and glucose metabolism compensation, the connection of the G-allele with insulin resistance, both hepatic (HOMA-IR) and associated with adipose tissue (HOMA-IR/adiponectin, adiponectin/leptin) was observed. Carriers of the recessive allele are also characterized by an increased atherogenic coefficient relative to the dominant CC genotype, a significant decrease in the levels of adiponectin (total and high molecular weight) and omentin, and an increase in the levels of leptin and vaspin in the circulation. According to the recessive model, the presence of the G-allele is accompanied by a weak but probable increase in the levels of highly sensitive C-reactive protein (CC vs. CG+GG: 1.92±0.42 mg/l vs. 4.62±0.94 mg/l, P &lt;0.05). The above suggests that the G-allele may be a predictor of a greater risk of cardiovascular disease development in patients with T2DM. Conclusions. It has been proven that the P72R polymorphism of the TP53 gene is functional for the East Ukrainian population, because against the background of a comparable degree of obesity and glucose metabolism compensation, carriers of the minor G-allele are characterized by a greater degree of insulin resistance and a proatherogenic shift in the hormonal activity of adipose tissue. A tendency to increase in frequency of the G-allele in men with type 2 diabetes was revealed, and it was determined that carriers of the minor genotype are characterized by a significantly younger age of diabetes manifestation. The obtained results substantiate the need for further research to assess the role of this polymorphism in the Ukrainian population.

Could Vaspin Be a Potential Diagnostic Marker in Endometrial Cancer?

Obesity and being overweight are risk factors for many types of cancer, including endometrial cancer. Adipose tissue is thought to be an endocrine organ that produces various hormones, including one known as vaspin. Insulin resistance, metabolic syndrome and type 2 diabetes are all associated with higher vaspin levels. A total of 127 patients divided into study (endometrial cancer) and control groups (non-cancerous) participated in this research. Serum vaspin levels were measured for all patients. The analysis was performed while taking into account grading and staging. In order to assess the usefulness of the tested protein as a new diagnostic marker, we used the plotting of a curve (ROC) and the calculation of the AUC curve to characterize the sensitivity and specificity of the parameters tested. We concluded that there were significantly lower vaspin levels in patients with endometrial cancer compared to patients with benign endometrial lesions. Vaspin may be a useful diagnostic marker in separating benign lesions from endometrial cancer.

Association of Serum Vaspin Concentration with Metabolic Disorders in Obese Individuals

Vaspin, a molecule produced in visceral adipose tissue, seems to participate in the pathogenesis of metabolic disorders. The study aimed to determine the association of vaspin concentration with metabolic disorders in obese individuals. Forty obese patients and twenty normal-weight subjects underwent biochemical (fasting glucose, insulin, lipid profile, interleukin-6, hs-CRP, vaspin concentration), blood pressure, and anthropometric measurements. The HOMA-IR index was calculated. Serum vaspin concentrations in the obese group were significantly higher than in the control group (0.82 ± 0.62 vs. 0.43 ± 0.59; p < 0.001). Among the entire population, vaspin concentration was positively correlated with body weight, BMI, WHR, and the percentage and mass of adipose tissue. Positive correlations between vaspin concentration and triglyceride level, insulin concentration, and HOMA-IR value were found. Vaspin concentration was positively correlated with hs-CRP and IL-6 levels. In obese patients, positive correlations between vaspin concentration and the percentage of adipose tissue and hs-CRP level were demonstrated. Logistic regression analysis showed that increased BMI was the biggest factor stimulating vaspin concentrations (OR = 8.5; 95% CI: 1.18-61.35; p = 0.0338). An elevated vaspin level may imply its compensatory role against metabolic disorders in obese patients. Thus, vaspin appears to be a useful diagnostic parameter for new therapeutic approaches in obesity-related complications. Nevertheless, due to the small sample size, further studies are needed to confirm our results.

Assessment of Serum Irisin and Vaspin in Women with Polycystic Ovary Syndrome in Mosul City

Patients with “polycystic ovary syndrome” (PCOS) may have changes in adipokine levels due to obesity rather than PCOS per se. This should be taken into account as there is a correlation between adipokine levels and BMI. The objective of the subsequent investigation was to measure serum levels of irisin and vaspin in women with PCOS. In the following study, overall, 140 sample size was selected for the evaluation. These 140 were divided into two groups in which 70 women were on the one group which was the intervention group, and 70 women were in control group. The control group of the study were the women who reportedly had regular and normal menstrual cycle. The results indicated high values of vaspin and irisin. The results of this study and previously published literature suggest that both adipocytokines are associated with high blood glucose levels and higher BMI, and finally, both values remain higher in women with PCOS. Vaspin and irisin could be considered as a biomarker for prognosis and therapy followup in patients with PCOS.

Correlation of plasma adipokines with endometrial atypical hyperplasia and type I/II endometrial cancer

The aim of the study was to systematically explore the relationships between various adipokines and risks of endometrial atypical hyperplasia (EAH), type I endometrial cancer (EC), and type II EC. We enrolled 219 patients in this study, including 39 EAH, 87 type I EC, 38 type II EC and 55 control individuals. We subsequently explored the association of adipokine levels and the leptin-to-adiponectin (L/A) ratio with EAH, type I EC, and type II EC. The plasma leptin level and L/A ratio were significantly higher in the EAH group than in the control group (p = 0.012). Leptin, resistin, vaspin, and visfatin levels were significantly higher in the type I EC group; however, the adiponectin level was lower in the type I EC, which resulted in a higher L/A ratio. Notably, the L/A ratio and visfatin level in the type II EC group were significantly higher. Multiple logistic regression analysis revealed that a higher leptin level was significantly associated with a higher EAH risk (p = 0.012). Higher leptin level (p = 0.042) and L/A ratio (p = 0.027) were significantly associated with an increased type I EC risk. By contrast, higher leptin (p = 0.059) and visfatin (p = 0.003) levels, higher L/A ratio (p = 0.033), and lower adiponectin level (p = 0.042) were associated with an increased type II EC risk. We suggested that adipokines are potentially correlated with EAH and EC risks.

Visceral adipose tissue-directed human kallistatin gene therapy improves adipose tissue remodeling and metabolic health in obese mice

ObjectiveAdipose tissue remodeling is a dynamic process that is pathologically expedited in the obese state and is closely related to obesity-associated disease progression. This study aimed to explore the effects of human kallistatin (HKS) on adipose tissue remodeling and obesity-related metabolic disorders in mice fed with a high-fat diet (HFD). MethodsAdenovirus-mediated HKS cDNA (Ad.HKS) and a blank adenovirus (Ad.Null) were constructed and injected into the epididymal white adipose tissue (eWAT) of 8-weeks-old male C57B/L mice. The mice were fed normal or HFD for 28 days. The body weight and circulating lipids levels were assessed. Intraperitoneal glucose tolerance test (IGTT) and insulin tolerance test (ITT) were also performed. Oil-red O staining was used to assess the extent of lipid deposition in the liver. Immunohistochemistry and HE staining were used to measure HKS expression, adipose tissue morphology, and macrophage infiltration. Western blot and qRT-PCR were used to evaluate the expression of adipose function-related factors. ResultsAt the end of the experiment, the expression of HKS in the serum and eWAT of the Ad.HKS group was higher than in the Ad.Null group. Furthermore, Ad.HKS mice had lower body weight and decreased serum and liver lipid levels after four weeks of HFD feeding. IGTT and ITT showed that HKS treatment maintained balanced glucose homeostasis. Additionally, inguinal white adipose tissue (iWAT) and eWAT in Ad.HKS mice had a higher number of smaller-size adipocytes and had less macrophage infiltration than Ad.Null group. HKS significantly increased the mRNA levels of adiponectin, vaspin, and eNOS. In contrast, HKS decreased RBP4 and TNFα levels in the adipose tissues. Western blot results showed that local injection of HKS significantly upregulated the protein expressions of SIRT1, p-AMPK, IRS1, p-AKT, and GLUT4 in eWAT. ConclusionsHKS injection in eWAT improves HFD-induced adipose tissue remodeling and function, thus significantly improving weight gain and dysregulation of glucose and lipid homeostasis in mice.

Внесок деяких біологічно активних речовин жирової тканини в розвиток серцево-судинних ускладнень у коморбідних пацієнтів

The contribution of some biologically active substances of adipose tissue to the development of cardiovascular complications in comorbid patients. Adipose tissue hormones — adipokines — vaspin and omentin, which control homeostasis, lipid and glucose metabolism, have attracted scientific interest in recent years. The purpose of the study was to determine the contribution of some hormones of adipose tissue, namely, vaspin and omentin, in the development of obesity in patients with coronary heart disease with concomitant obesity. Materials and methods. A comprehensive examination of 38 patients with coronary heart disease in combination with obesity (average age: 64±1.9 years), men and women in equal numbers, was conducted; the comparison group consisted of 40 patients with coronary artery disease without obesity. Control group: 20 practically healthy individuals without coronary heart disease and with normal body weight, average age 58.2±1.4 years. Conclusions: The comorbidity of coronary heart disease and obesity leads to the activation of the pro-inflammatory hormone of adipose tissue — vaspin and insufficient circulation of omentin, which leads to an increase in body weight. The development of obesity in patients with coronary heart disease depends on the dysfunction of adipose tissue, the manifestations of which are an imbalance in the levels of vaspin and omentin.

Assessment of serum levels of vaspin in a sample of Iraqi patients with prediabetes and newly diagnosed type II diabetes mellitus

Assessment of serum levels of vaspin in a sample of Iraqi patients with prediabetes and newly diagnosed type II diabetes mellitus